Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Eosinophilic COPD Following Hospital Admission
NCT04075331Phase 3Completed
- Sponsor
- University of Leicester
- Start
- Sep 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in chronic obstructive pulmonary disease (COPD), sponsored by University of Leicester. Started Sep 2020; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04075331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075331.